Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 1,190 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Leslie Norwalk sold 1,190 shares of Neurocrine Biosciences stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $155.09, for a total transaction of $184,557.10. Following the completion of the transaction, the director owned 6,239 shares in the company, valued at approximately $967,606.51. This trade represents a 16.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock traded down $7.04 during trading hours on Wednesday, reaching $141.70. 1,740,144 shares of the stock were exchanged, compared to its average volume of 1,152,484. Neurocrine Biosciences, Inc. has a 52-week low of $84.23 and a 52-week high of $160.18. The stock has a market cap of $14.13 billion, a P/E ratio of 33.90, a P/E/G ratio of 1.01 and a beta of 0.27. The firm’s 50 day moving average is $145.88 and its 200 day moving average is $137.74.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Tuesday, October 28th. The company reported $2.17 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.59. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. The business had revenue of $794.90 million for the quarter, compared to the consensus estimate of $746.61 million. During the same quarter in the previous year, the firm earned $1.81 earnings per share. The business’s quarterly revenue was up 27.8% compared to the same quarter last year. Equities research analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Institutional Trading of Neurocrine Biosciences

Several large investors have recently bought and sold shares of NBIX. American Century Companies Inc. boosted its position in shares of Neurocrine Biosciences by 106.6% in the 1st quarter. American Century Companies Inc. now owns 191,182 shares of the company’s stock worth $21,145,000 after buying an additional 98,659 shares in the last quarter. Korea Investment CORP raised its position in Neurocrine Biosciences by 42.4% during the first quarter. Korea Investment CORP now owns 86,989 shares of the company’s stock worth $9,621,000 after acquiring an additional 25,900 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Neurocrine Biosciences by 44.0% in the first quarter. Wellington Management Group LLP now owns 2,097,981 shares of the company’s stock valued at $232,037,000 after purchasing an additional 640,556 shares in the last quarter. Hsbc Holdings PLC grew its position in shares of Neurocrine Biosciences by 14.4% in the first quarter. Hsbc Holdings PLC now owns 243,035 shares of the company’s stock valued at $26,887,000 after purchasing an additional 30,681 shares during the last quarter. Finally, Banco Bilbao Vizcaya Argentaria S.A. increased its stake in shares of Neurocrine Biosciences by 2.6% during the 1st quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 143,369 shares of the company’s stock worth $15,857,000 after purchasing an additional 3,699 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on NBIX. JPMorgan Chase & Co. increased their target price on Neurocrine Biosciences from $171.00 to $179.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Piper Sandler upped their price objective on Neurocrine Biosciences from $175.00 to $179.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. Needham & Company LLC increased their price objective on Neurocrine Biosciences from $170.00 to $184.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. TD Cowen boosted their target price on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Finally, Mizuho increased their price target on shares of Neurocrine Biosciences from $146.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $174.76.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.